KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $2.3 billion.

  • Royalty Pharma's Retained Earnings fell 1665.18% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year decrease of 1665.18%. This contributed to the annual value of $2.8 billion for FY2024, which is 1303.11% up from last year.
  • As of Q3 2025, Royalty Pharma's Retained Earnings stood at $2.3 billion, which was down 1665.18% from $2.2 billion recorded in Q2 2025.
  • Royalty Pharma's 5-year Retained Earnings high stood at $2.8 billion for Q4 2024, and its period low was $1.9 billion during Q1 2021.
  • Moreover, its 5-year median value for Retained Earnings was $2.3 billion (2025), whereas its average is $2.3 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 4585.51% in 2021, then tumbled by 1665.18% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Retained Earnings stood at $2.3 billion in 2021, then dropped by 12.88% to $2.0 billion in 2022, then increased by 28.14% to $2.5 billion in 2023, then increased by 13.03% to $2.8 billion in 2024, then dropped by 19.02% to $2.3 billion in 2025.
  • Its last three reported values are $2.3 billion in Q3 2025, $2.2 billion for Q2 2025, and $2.5 billion during Q1 2025.